BRAF and neoplasm: Xing, M. et al. [50] reported that 6.9% of all PTCs have concomitant mutations in TERTp and BRAF genes, which were significantly associated with clinicopathological features of worst prognoses and tumor progression, namely LNM, extra thyroidal, and vascular invasion.